Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Author:
Shun Lu,Jie Wang,Nong Yang,Dongqing Lv,Lijuan Chen,Lin Wu,Xingya Li,Longhua Sun,Yongfeng Yu,Bo Jin,Lin Yang,Yubiao Guo,Haipeng Xu,Tienan Yi,Aiping Zeng,Xiaorong Dong,Jianhua Chen,Ziping Wang,Hongrui Niu,Ying Cheng,Pinhua Pan,Pengbo Deng et al.
© 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.